Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619860 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
A Phase 2 study of Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06619860: Recruiting Phase 2 study of Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated.
NCT06619860 is a Phase 2 study of Diabetic Peripheral Neuropathic Pain that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 300 participants, below the 394-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06619860, a Phase 2 study of Diabetic Peripheral Neuropathic Pain, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Conditions Studied
Interventions
- DRUG VX-993
- DRUG Pregabalin
- DRUG Placebo (matched to pregabalin)
- DRUG Placebo (matched to VX-993)
Study Locations (20)
Florida
- Accel Research - Deland - DeLand
- AMR Fort Myers (The Clinical Study Center) - Fort Myers
- Velocity Clinical Research - Hallandale Beach - Hallandale
- Health Awareness, Inc., Jupiter - Jupiter
- Suncoast Research Associates - Miami - Miami
- Innovation Medical Research Center - Palmetto - Palmetto Bay
- Health Awareness, Inc. - Port St. Lucie - Port Saint Lucie
California
- Trovare Clinical Research - Bakersfield CA - Bakersfield
- Eximia Research - San Diego - La Mesa
Georgia
- Atlanta Center for Medical Research - Atlanta
- Accel Research - Decatur - Decatur
Alabama
- Cullman Clinical Trials - Cullman
Colorado
- Paradigm Clincial Research Centers, LLC., Wheat Ridge - Wheat Ridge
Idaho
- Velocity Clinical Research - Boise - Meridian
Illinois
- Healthcare Research Network - Flossmoor IL - Flossmoor
Michigan
- Quest Research Institute - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-10-18 |
| Est. Completion | 2026-05-30 |
| Phase | Phase 2 |
What NCT06619860 shows while recruiting
NCT06619860 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 394-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Diabetic Peripheral Neuropathic Pain appearing as the primary indexed condition, and to 4 interventions - of which VX-993 is the first listed.
NCT06619860 names 20 study sites across 12 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06619860 about?
NCT06619860 is a clinical study titled "Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy". The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
What is the current status of trial NCT06619860?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2024-10-18. Estimated completion is 2026-05-30.
What conditions does trial NCT06619860 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathic Pain.
What interventions are being tested in trial NCT06619860?
The interventions under investigation include: VX-993 (DRUG), Pregabalin (DRUG), Placebo (matched to pregabalin) (DRUG), Placebo (matched to VX-993) (DRUG).
Who is sponsoring clinical trial NCT06619860?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06619860 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
COMPLETED · Phase 2
-
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
COMPLETED · Phase 2
-
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI